Table 2.
Comparison of main outcomes between DAPA-HF, EMPEROR-Reduced and VICTORIA trial.
| Outcome | DAPA-HF (n=4744) | EMPEROR-Reduced (n=3730) | VICTORIA (n=5050) |
|---|---|---|---|
| Follow-up (months) | 18.2 | 16.0 | 10.8 |
| Primary outcomes rate: active/placebo (%) | |||
| Combined (CV death + HFH) | 16.3/21.2 | 19.4/24.7 | 33.6/37.8 |
| HFH | 10.0/13.7 | 10.7/15.5 | 27.4/29.6 |
| CV death | 9.6/11.5 | 7.6/8.1 | 8.2/8.9 |
| HR (95% CI) | |||
| Combined (CV death + HFH) | 0.74 (0.65–0.85) | 0.75 (0.65–0.86) | 0.90 (0.82–0.98) |
| HFH | 0.70 (0.59–0.83) | 0.69 (0.59–0.81) | 0.90 (0.81–1.00) |
| CV death | 0.82 (0.69–0.98) | 0.92 (0.75–1.12) | 0.93 (0.81–1.06) |
| AER: active/placebo (%) | |||
| Combined (CV death + HFH) | 11.6/15.6 | 15.8/21.0 | 33.6/37.8 |
| HFH | 6.9/9.8 | 10.7/15.5 | 25.9/29.1 |
| CV death | 6.5/7.9 | 7.6/8.1 | 12.9/13.9 |
| ARR (%) | |||
| Combined (CV death + HFH) | 4.0 | 5.2 | 4.2 |
| HFH | 2.9 | 4.8 | 2.7 |
| CV death | 1.4 | 0.6 | 1.0 |
| NNT | 25.0 | 19.2 | 23.8 |